Table 2 Association between FIASMA psychotropic medication use at baseline and risk of intubation or death among patients with psychiatric disorders hospitalized for severe COVID-19.

From: Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study

 

Number of events / Number of patients

Crude Cox regression analysis

Multivariable Cox regression analysisa

Analysis weighted by inverse- probability- weighting weightsa

Number of events / Number of patients in the matched groups

Univariate Cox regression in a 1:1 ratio matched analytic sample

Cox regression in a 1:1 ratio matched analytic sample adjusted for unbalanced covariatesb

 

N (%)

HR (95% CI; p-value)

HR (95% CI; p-value)

HR (95% CI; p-value)

N (%)

HR (95% CI; p-value)

HR (95% CI; p-value)

No FIASMA psychotropic medication

215 / 381 (56.4%)

Ref.

Ref.

Ref.

77 / 164 (47%)

Ref.

Ref.

Any FIASMA psychotropic medication

57 / 164 (34.8%)

0.42 (0.31–0.57; <0.001*)

0.49 (0.36–0.67; <0.001*)

0.50 (0.37–0.67; <0.001*)

57 / 164 (34.8%)

0.65 (0.45–0.93; 0.019*)

0.55 (0.39–0.77; 0.001*)

  1. aAdjusted for age, sex, hospital, obesity, and number of medical conditions.
  2. bAdjusted for sex and obesity.
  3. *Two-sided p-value is significant (p < 0.05).
  4. HR hazard ratio, CI confidence interval.
  5. Non-FIASMA psychotropic medications include medications that have either no or a relatively low in vitro FIASMA effect corresponding to an in vitro residual ASM activity lower than 50%, or for which the FIASMA effect status is unknown.
Back to article page